To match an exact phrase, use quotation marks around the search term. eg. "Parliamentary Estate". Use "OR" or "AND" as link words to form more complex queries.

Keep yourself up-to-date with the latest developments by exploring our subscription options to receive notifications direct to your inbox

MP Financial Interest
Ian Murray (Labour - Edinburgh South)
Original Source (15th April 2024)
7. (i) Shareholdings: over 15% of issued share capital
Name of company or organisation: 100MPH Events Limited (dormant)
Nature of business: Event management
(Updated 31 July 2023)
MP Financial Interest
Ian Murray (Labour - Edinburgh South)
Original Source (15th April 2024)
8. Miscellaneous
Director of 100MPH Events Limited (dormant). This is an unpaid role.
Date interest arose: 22 October 2001
(Registered 31 July 2023)
MP Financial Interest
Ian Murray (Labour - Edinburgh South)
Original Source (15th April 2024)
8. Miscellaneous
Director of the Commonwealth Parliamentary Association (United Kingdom).
Date interest arose: 12 July 2017
(Registered 31 July 2023)
MP Financial Interest
Ian Murray (Labour - Edinburgh South)
Original Source (15th April 2024)
8. Miscellaneous
Trustee of the Royal Observatory Trust. This is an unpaid role.
Date interest arose: 1 October 2010
(Registered 2 August 2023)
MP Financial Interest
Ian Murray (Labour - Edinburgh South)
Original Source (15th April 2024)
8. Miscellaneous
Director of IM Campaigns Ltd (dormant). This is an unpaid role.
Date interest arose: 2 June 2020
(Registered 31 July 2023)
MP Financial Interest
Ian Murray (Labour - Edinburgh South)
Original Source (15th April 2024)
8. Miscellaneous
Trustee of McRaes Batallion Trust. This is an unpaid role.
Date interest arose: 1 May 2004
(Registered 2 August 2023)
Division Vote (Commons)
25 Mar 2024 - Investigatory Powers (Amendment)Bill [Lords] - View Vote Context
Ian Murray (Lab) voted Aye - in line with the party majority and against the House
One of 120 Labour Aye votes vs 0 Labour No votes
Vote Tally: Ayes - 171 Noes - 265
Division Vote (Commons)
25 Mar 2024 - Investigatory Powers (Amendment)Bill [Lords] - View Vote Context
Ian Murray (Lab) voted Aye - in line with the party majority and against the House
One of 121 Labour Aye votes vs 0 Labour No votes
Vote Tally: Ayes - 171 Noes - 265
Written Question
Advanced Therapy Medicinal Products: Scotland
Friday 22nd March 2024

Asked by: Ian Murray (Labour - Edinburgh South)

Question to the Department for Science, Innovation & Technology:

To ask the Secretary of State for Science, Innovation and Technology, what steps her Department is taking to help support research into cell and gene therapy in Scotland.

Answered by Andrew Griffith - Minister of State (Department for Science, Innovation and Technology)

The UK is a world-leader in the development and manufacture of cell and gene therapies thanks to government investment in innovation and skills, including through the Cell and Gene Therapy Catapult (CGTC).

DSIT also invested £10 million - alongside £10 million from Scottish Enterprise – to support a new Oligonucleotide Manufacturing Innovation Centre of Excellence in Glasgow.

The Vaccine Taskforce provided funding for a state-of-the art CGTC facility in Braintree to accelerate the development and manufacturing of advanced therapies at clinical and commercial scale.

My department also supported CGTC to establish apprenticeships and training programmes to upskill people across the UK.

Written Question
Advanced Therapy Medicinal Products: Scotland
Thursday 21st March 2024

Asked by: Ian Murray (Labour - Edinburgh South)

Question to the Department for Science, Innovation & Technology:

To ask the Secretary of State for Science, Innovation and Technology, what steps her Department is taking to increase Scotland’s (a) manufacturing capacity for and (b) delivery of cell and gene therapies.

Answered by Andrew Griffith - Minister of State (Department for Science, Innovation and Technology)

The government is investing significantly to support manufacturing and delivery of cell and gene therapies.

Since 2021, government has launched three UK-wide capital grant schemes – up to £118 million of funds – to incentivise manufacturing investments, including in advanced therapies. Last year, government announced a further £520 million to increase investment in Life Sciences manufacturing.

The UK is a world-leader in the development and manufacture of cell and gene therapies thanks to government investment in innovation and skills, including through the Cell and Gene Therapy Catapult which also coordinates the Advanced Therapy Treatment Centre network.